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Abstract Implantation of a coronary stent results in
a mechanical enlargement of the coronary lumen with
stretching of the surrounding atherosclerotic plaque.
Using intravascular ultrasound virtual-histology
(IVUS-VH) we examined the temporal changes in
composition of the plaque behind the struts (PBS)
following the implantation of the everolimus eluting
bioresorbable vascular scaffold (BVS). Using IVUS-
VH and dedicated software, the composition of plaque
was analyzed in all patients from the ABSORB B trial
who were imaged with a commercially available
IVUS-VH console (s5i system, Volcano Corporation,
Rancho Cordova, CA, USA) post-treatment and at
6-month follow-up. This dedicated software enabled
analysis of the PBS after subtraction of the VH signal
generated by the struts. The presence of necrotic core
(NC) in contact with the lumen was also evaluated at
baseline and follow-up. IVUS-VH data, recorded with
s5i system, were available at baseline and 6-month
follow-up in 15 patients and demonstrated an increase in
both the area of PBS (2.45 ± 1.93 mm2 vs. 3.19 ±
2.48 mm2, P = 0.005) and the external elastic mem-
brane area (13.76 ± 4.07 mm2 vs. 14.76 ± 4.56 mm2,
P = 0.006). Compared to baseline there was a signif-
icant progression in the NC (0.85 ± 0.70 mm2 vs.
1.21 ± 0.92 mm2, P = 0.010) and fibrous tissue area
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(0.88 ± 0.79 mm2 vs. 1.15 ± 1.05 mm2, P = 0.027)
of the PBS. The NC in contact with the lumen in the
treated segment did not increase with follow-up (7.33
vs. 6.36%, P = 0.2). Serial IVUS-VH analysis of BVS-
treated lesions at 6-month demonstrated a progression in
the NC and fibrous tissue content of PBS.
Keywords Bioresorbable vascular scaffold 
Coronary plaque  IVUS-VH  Everolimus
Introduction
Percutaneous treatment of atherosclerotic lesions has
been improved by the introduction of bare- and drug-
eluting metallic stents [1]. Implantation of a metallic
stent does not remove atherosclerotic plaque; instead
the plaque is stretched during baro-trauma. The
metallic stent platform and the eluted drug may affect
not only the intra-stent neo-intima growth, but also the
plaque behind the struts. With regards to the vascular
response to a foreign body (i.e. a metallic stent), [2, 3]
animal models have demonstrated that metallic stents
eluting sirolimus and paclitaxel induce inflammatory
changes adjacent to almost all struts [4].
Evaluation of plaque behind the metallic struts can
be performed using intravascular ultrasound virtual
histology (IVUS-VH), which facilitates qualitative
and quantitative analyses of the plaque. Since metal-
lic stent’s struts are mistakenly recognized by IVUS-
VH as dense calcium and necrotic core, careful
evaluation of the sole plaque behind the stent struts
should be done to avoid any misclassification of the
actual tissue [5, 6]. Previous reports using serial
IVUS-VH analysis of lesions treated with drug-
eluting stents have demonstrated a greater frequency
of ‘‘unstable lesion morphometry’’ at follow-up,
compared with bare metal stents [7]. Temporary
scaffolding with a everolimus eluting bioresorbable
vascular scaffold (BVS; Abbott Vascular, Santa
Clara, USA) may have differential effects on peri-
strut plaque, due to the polymeric nature of the fast
resorbable coating made of a mixture of L and D
racemic forms of poly-lactide [8].
Therefore, we assessed the vascular response to
implantation of the BVS at 6-months follow-up using
IVUS-VH, and customized software to selectively
analyze the plaque behind the struts.
Methods
Study population
For the present analysis, we initially screened patients
from Cohort B1 of the ABSORB trial with paired
post-implantation and 6-month follow-up IVUS-VH.
Briefly, ABSORB Cohort B trial enrolled patients
older than 18 years, with a diagnosis of stable,
unstable or silent ischemia. This trial was subdivided
in two subgroups of patients: the first group (cohort
B1) has to undergo invasive imaging such as QCA,
IVUS, IVUS-VH and OCT at 6 and 24 months
whereas the second group (cohort B2) will undergo
this invasive imaging at 12 and 24 months. All
lesions were de novo, in a native coronary artery with
a reference vessel diameter of 3.0 mm, with a %
diameter stenosis C50 and \100% and a thrombol-
ysis in myocardial infarction (TIMI) flow grade of
C1. All lesions were treated by implantation of the
BVS revision 1.1 (3.0 9 18 mm). Major exclusion
criteria were: patients presenting with an acute
myocardial infarction, unstable arrhythmias or
patients who had left ventricular ejection fraction
B30%, restenotic lesions, lesions located in the left
main coronary artery, lesions involving a side branch
[2 mm in diameter, and the presence of thrombus or
another clinically significant stenosis in the target
vessel. This trial was approved by ethics committee at
each participating institution and each patient gave
written informed consent before inclusion.
The BVS has an amorphous poly-DL-lactide
(PDLLA) coating that contains and controls the
release of the anti-proliferative drug everolimus. The
scaffold body is made of semi-crystalline poly-L-
lactide (PLLA). PLA is completely degraded via
hydrolysis and bioresorbed via the Krebs cycle [8, 9].
Lesions were treated with routine interventional
techniques that included mandatory pre-dilatation
using a balloon shorter than the study device and
0.5 mm less in diameter. All patients were pre-
treated with aspirin and a loading dose of at least
300 mg of clopidogrel was administered according
to local hospital practise. After the procedure, all
patients received aspirin C75 mg for the study
duration (5 years) and clopidogrel 75 mg daily for
a minimum of 6 months. Anticoagulation and gly-
coprotein IIb/IIIa use was according to local hospital
practice.
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Imaging procedure and acquisition
IVUS-VH post-implantation and 6 months follow-up
were acquired with a phased array 20 MHz intravas-
cular ultrasound catheter (EagleEyeTM; Volcano
Corporation, Rancho Cordova, CA, USA) using an
automated pullback of 0.5 mm per second. These
files were stored on DVD and sent to the Corelab for
independent analyses (Cardialysis, BV, Rotterdam,
The Netherlands).
Image analysis
Customized offline IVUS-VH software was the
QIVUs (Medis, Leiden, The Netherlands). Unlike
other IVUS-VH software (pcVH and VIAS), this
package allows the user to draw, in a semi-automatic
fashion, a third contour (i.e. the scaffold contour). One
limitation, however, is the ability of the software to
read only IVUS-VH data acquired using a specific
commercially available IVUS-VH console (s5i sys-
tem, Volcano Corporation, Rancho Cordova, CA,
USA). Contour detection was performed by experi-
enced IVUS analysts who were blinded to the time of
acquisition of the data (e.g. baseline or 6-month
follow-up) [10]. Four tissue components (necrotic
core—red; dense calcium—white; fibrous—green;
and fibrofatty—light green) were identified with
autoregressive classification systems. Each individual
tissue component was quantified and colour coded in
all IVUS cross sections as previously described [8, 11].
It has already been reported that the polymeric
struts of the BVS (150 lm strut’s thickness) are mis-
interpreted by IVUS-VH as areas of apparent ‘‘dense
calcium’’ and ‘‘necrotic core’’, [8] therefore drawing
this third contour, behind the polymeric struts of the
BVS, delineates a new region of interest excluding the
polymeric struts and their ultrasonic signature (Fig. 1).
In addition, we evaluated the presence of necrotic
core in contact with the lumen, defined as a confluent
necrotic core [10% of plaque area without evidence
of overlying non-necrotic core tissue in the treated
segment and in the edges (5 mm length adjacent to
each BVS edge). Importantly, as polymeric struts are
recognized as dense calcium surrounded by necrotic
core, this surrounding necrotic core identified with
the help of the corresponding grey-scale image, was
not interpreted as necrotic core in contact with the
lumen [5, 7, 12].
Ultimately, we drew the interface between pla-
que ? media and the adventitia (external elastic
membrane area, EEM), as well as the contours of
the BVS area. We calculated the plaque area behind
the struts (PBS) as the sum of all IVUS-VH
components of the plaque behind the struts, excluding
the grey medial stripe seen with IVUS-VH.
Statistical analysis
Discrete variables are presented as counts and per-
centages. Continuous variables are presented as
means ± standard deviation (SD). The calculation of
the changes of each IVUS-VH plaque component
between post-treatment and 6 months was as follows:
mean 6 months area minus mean post-procedure area.
The ratio between the number of frames with necrotic
core in contact with the lumen and the total number of
frames analyzed has been defined as incidence of
necrotic core in contact with the lumen for the treated
segment and the edges. Paired comparisons between
Fig. 1 Panel A: one frame of grey-scale IVUS indicating the
appearance of the BVS’s struts (double grey line). In Panel B
the polymeric struts are recognized as dense calcium and
necrotic core by IVUS-VH and in (Panel C) a third contour
(purple line) is drawn in a semi-automatic way by the
dedicated software behind them
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post-procedure and 6-month follow-up were done by
the Wilcoxon signed rank test. Correlation between
parameters was performed by Spearman test. A two-
side P value of less than 0.05 indicated statistical
significance. Intra-observer and inter-observer vari-
abilities were measured by correlation test for IVUS
data and by j test of concordance for necrotic core in
contact with the lumen. Statistical analyses were
performed with use of SPSS 13.0 software.
Results
Baseline clinical and angiographic characteristics
Thirty-two patients in the ABSORB Cohort B study
had paired post- implantation and 6-month IVUS-VH
data. Out of these 32 patients, only 15 patients were
imaged using the s5i system. Table 1 shows their
clinical and angiographic data.
Grey-scale IVUS and IVUS-VH analyses
(Table 2)
A significant increase in both EEM area and of PBS
was observed with follow-up. A non significant 4%
decrease in BVS area was observed at follow up
(P = 0.065).
In the IVUS-VH analysis of the plaque behind the
polymeric struts, there was a significant relative
increase of 30% in fibrous tissue area (from
0.88 ± 0.79 mm2 to 1.15 ± 1.05 mm2; P = 0.027)
and of 42% in necrotic core area (from 0.85 ±
0.70 mm2 to 1.21 ± 0.92 mm2; P = 0.010) at 6-
month follow-up. There was a no significant increase
of 3% in fibrofatty tissue area (P = 0.286) and 8% in
dense calcium area (P = 0.334). However, the per-
centage weight of each plaque component did not
change significantly.
There was a significant correlation between D
plaque behind the polymeric struts and D mean EEM
area (r = 0.9, P \ 0.001; Fig. 2) There was no
Table 1 Clinical and angiographic characteristics of the
patients
Patients (n = 15)
Lesions (n = 15)
Age (years)
Mean ± SD (n) 63.87 ± 12.01
Men (%) 60.0
Smokers (%) 26.7
Diabetes (%) 13.3
Hypertension requiring medication (%) 66.7
Hyperlipidaemia requiring medication (%) 80.0
Previous target vessel intervention (%) 6.7
Previous myocardial infarction (%) 53.3
Stable angina (%) 53.3
Unstable angina (%) 33.3
Silent ischaemia (%) 6.7
Target vessel (%)
Left anterior descending 33.3
Left circumflex 26.7
Right coronary artery 40.0
AHA/ACC lesion classification (%)
A 6.7
B1 33.3
B2 53.3
C 6.7
Beta-blocker 93.3
ACEI/ARB 40.0
Calcium-channel blocker 40.0
Statin 100.0
SD standard deviation; ACEI angiotensin-converting enzyme
inhibitor; ARB angiotensin receptor blocker
Table 2 IVUS analysis in the treated segment at baseline and
follow-up
BVS 1.1 (n = 15) P value
Baseline Follow-up
Mean EEM area
(mm2)
13.76 ± 4.07 14.76 ± 4.56 0.006
PBS area (mm2) 2.45 ± 1.93 3.19 ± 2.48 0.005
BVS area (mm2) 6.51 ± 1.38 6.25 ± 1.14 0.065
Fibrous tissue (mm2) 0.88 ± 0.79 1.15 ± 1.05 0.027
Fibrous tissue (%) 38.80 ± 16.36 35.86 ± 13.25 0.256
Fibro-fatty tissue
(mm2)
0.18 ± 0.36 0.20 ± 0.40 0.286
Fibro-fatty tissue
(%)
5.31 ± 7.82 4.43 ± 6.70 0.532
Necrotic core (mm2) 0.85 ± 0.70 1.21 ± 0.92 0.010
Necrotic core (%) 37.23 ± 11.66 40.18 ± 8.69 0.307
Dense calcium
(mm2)
0.54 ± 0.85 0.62 ± 0.72 0.334
Dense calcium (%) 18.66 ± 14.06 19.52 ± 12.77 0.691
Data are expressed as mean ± SD
EEM external elastic membrane; PBS plaque behind struts;
BVS bioresorbable vascular scaffold
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correlation between D plaque behind the struts and
the change in BVS area (P = 0.9).
Incidence of necrotic core in contact with the lumen
A representative IVUS image of necrotic core in
contact with the lumen in the BVS treated segment is
shown in Fig. 3. There was no significant change
during follow-up in the content of the necrotic core in
contact with the lumen in the treated segment (7.33
vs. 6.36%, P = 0.256; Fig. 4).
Intra-observer and inter-observer variabilities
Intra-observer and inter-observer variabilities yielded
good concordance for IVUS data (r2 = 0.91 and
r2 = 0.87, respectively) and for necrotic core in contact
with the lumen (j = 0.96 and j = 0.90, respectively)
Discussion
The major findings of our study are: (1) at 6 months
follow-up, the increase in plaque area, and in particular
the progression of necrotic core and fibrous tissue
detected by IVUS-VH behind the polymeric struts,
correlated to an increase in EEM area; (2) although
there was an increase in necrotic core area behind the
polymeric struts, there was not an increase in necrotic
core in contact with the lumen in the treated segment.
Fig. 3 Representative IVUS-VH image of necrotic core in contact with the lumen in the segment where a BVS has been implanted
(white arrows). BVS bioresorbable polymeric scaffold
Fig. 4 Incidence of segments with necrotic core abutting the
lumen at baseline and follow-up. Within the treated lesion site,
proximal and distal reference segment necrotic core abutting
the lumen did not significantly modify
Fig. 2 Correlation between the temporal change of the plaque
behind the polymeric struts and of EEM area. EEM external
elastic membrane
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Similar to metallic stents, struts of the BVS are
detected by IVUS-VH as dense calcium, surrounded
by a ‘‘red halo’’ [5, 12]. This observation may be
useful for the evaluation of the bioresorption process
of the BVS, as temporal changes in dense calcium
and necrotic core of coronary segments treated with a
BVS appear to be a ‘surrogate’ of the bioresorption
process [6, 12]. However, this misinterpretation of
the polymeric struts by IVUS-VH prevents analysis
of the actual amount of dense calcium and necrotic
core within the plaque behind the struts. The semi-
automatic introduction by the ‘‘Medis software’’ of a
third contour, which represents the BVS, is a helpful
tool to focus analysis on only the plaque behind the
BVS. We acknowledge that this software has not
previously validated for this use and in our analysis it
has shown a good the inter- and intra-observers
variabilities.
Previously Kubo et al. analyzed the long-term
effects of drug-eluting stents (DES) and bare metal
stents (BMS) on coronary arterial wall morphology
using IVUS-VH, and demonstrated that DES-treated
lesions had a greater frequency of ‘‘unstable lesion
morphometry’’ at follow-up compared to BMS [7]. In
particular assessing the total amount of the four
IVUS-VH components, including also the contribu-
tion of the stent, it was found that DES-treated lesions
showed a significantly higher incidence of necrotic
core in contact with the lumen compared to BMS-
treated lesions at follow up, although there was no
significant difference in mean necrotic core area
between both groups. This was due to a suppression
of the protective neointimal hyperplasia layer with
DES compared with BMS. In our study, focusing
only on plaque burden behind the polymeric struts,
we found a significant progression in necrotic core
and fibrous tissue at 6 months follow-up. However,
the incidence of necrotic core in contact with the
lumen behind polymeric struts did not tend to
increase during the same period. Histological valida-
tion studies have shown that necrotic core is a mainly
highly lipid necrotic region with remnants of foam
cells and some infiltration of inflammatory cells. It is
unlikely that the changes described in the plaque
behind the polymeric struts are influenced by changes
in the BVS struts during the first 6 months: it has
been, indeed, shown that the 100% of the boxes of the
BVS, evaluated by optical coherence tomography, are
preserved with completely absence of qualitative
alterations, whereas only 3% of the boxes of the first
BVS generation appeared as ‘‘preserved’’ [13].
Recently concerns have been raised over the long-
term biological reaction to metallic DES [14]. In rabbit
iliac arteries, evidence of increased inflammation and
delayed endothelialization was noted at 28 days in
DES compared with polymer-coated inert stents or
BMS [15]. In porcine coronary arteries treated with
DES, arterial inflammation characterized by giant cells
has been shown to gradually progress from 90 to
180 days with a corresponding increase in neointimal
formation [16]. In humans, Aoki et al. have demon-
strated in vivo that plaque volume behind a metallic
stent eluting sirolimus increases slightly at 4 months
follow-up, and then significantly decreases at 4 years
follow-up compared to post-implantation, and that
change in echogenicity is suggestive of a change in
plaque composition [17]. The same phenomenon was
observed following implantation of an everolimus-
eluting metallic stent in the SPIRIT I study: slight
increase of plaque behind the stent at 6 months,
followed by a decrease at 1 year follow-up [18]. Aoki
et al. also documented a significant increase in plaque
area behind metallic stents eluting paclitaxel at
6 months, with subsequent regression at 2 years [19].
In the MAHOROBA study, that tested biodegradable
polymer sustained release tacrolimus-eluting stent,
Onuma et al. have shown that plaque volume increased
significantly at 4-month angiographic follow-up [20].
In our study, at 6 months follow-up, we observed an
increase of both plaque area and of necrotic core
behind the polymeric struts of BVS.
Some preclinical studies in an atherosclerotic rabbit
model have shown that the implantation of metallic
everolimus eluting stents results in an autophagic
process of macrophages through the inhibition of the
mTOR pathway by everolimus [21, 22]. In a porcine
model, Onuma et al. found inflammatory cells, in
particular granuloma and giant cells, surrounding the
polymeric struts of the BVS: the concentration of cells
was highest 1 and 6 months after implantation, before
decreasing over time [23]. In particular after 1 year
there was a decrease in the inflammation score,
granulomas and giant cells surrounding the polymeric
struts. It is important to highlight that in the porcine
coronary artery model, BVS associated inflammation
is markedly less than with a sirolimus-eluting metallic
stent. In humans at 6 months after BVS 1.0 implan-
tation and with long-term follow-up Sarno et al. found
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a similar increase of plaque area at 6-month, with a
following decrease at 2 years, most likely due to the
bioresorption of the polymeric struts [6].
It is also important to consider that the increase in
plaque area, as a result mainly of necrotic core and
fibrous tissue progression, did not translate into a
decrease of a scaffold area of BVS, but only in a
positive remodelling of the EEM [24]. Rodriguez-
Granillo et al. have already shown how positive
remodelling of the vessel may be related to plaque
composition: in particular lipid core size was signif-
icantly larger in positively remodelled coronary
lesions than in those with vessel shrinkage [24].
Limitations
The present study included a very small number of
patients with a technique (VH) that has large variabil-
ity. The use of the same patients at baseline and follow-
up may reduce its variability. However, the intra- and
inter-catheter variability of the VH previously shown
supports longitudinal studies with the VH [25].
IVUS-VH data pre-BVS implantation were not
available, therefore baseline characteristics of the
artery have been evaluated in the presence of the
BVS, and after pre-dilatation.
The interpretation of the backscattering signal from
the plaque behind the polymeric struts by the IVUS-
VH software may be influenced by the presence of the
scaffold: analysis of the difference between 6-month
follow-up and baseline may reduce this limitation.
Conclusions
In conclusion our study focusing on the IVUS-VH
detection of plaque behind the BVS seems to show a
progression in necrotic core and fibrous tissue
components at 6 months. In particular, the progres-
sion in necrotic core confirms the histological data in
animal models regarding an inflammatory microen-
vironment behind the polymeric struts, at least at
6-month follow-up.
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